Status:

COMPLETED

Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients

Lead Sponsor:

Fresenius Kabi

Collaborating Sponsors:

B. Braun Melsungen AG

European Society of Anaesthesiology and Intensive Care

Conditions:

Hypovolemia Due to Acute Blood Loss

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The aim of the study is to investigate the safety of a 6% hydroxyethyl starch (HES) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in trauma patients.

Eligibility Criteria

Inclusion

  • Inclusion:
  • Male or female adult patients ≥18 years of age. Women of child bearing potential must test negative on standard pregnancy test (urine or serum) (as soon as possible during emergency care)
  • Patients with blunt or penetrating trauma suffering from estimated blood loss of ≥ 500 ml
  • Initial surgery deemed necessary within 24 hrs after trauma
  • Deferred signed written informed consent form or as locally required
  • No signs of intracranial or cerebral hemorrhage
  • Administration of less than 15 ml/kg body weight colloid between trauma injury and hospital admission.
  • Exclusion:
  • Hypersensitivity to the active substances or to any of the other excipients of the Investigational Products
  • Body weight ≥ 140 kg
  • Patients expected to die within 24h after traumatic injury
  • Sepsis
  • Burns
  • Renal impairment (AKIN stage ≥ 1 or chronic) or acute and/or chronic Renal Replacement Therapy
  • Critically ill patients (typically admitted to the intensive care unit)
  • Hyperhydration
  • Pulmonary edema
  • Dehydration
  • Hyperkalemia
  • Severe hypernatremia
  • Severe hyperchloremia
  • Severely impaired hepatic function
  • Congestive heart failure
  • Severe coagulopathy
  • Organ transplant patients
  • Metabolic alkalosis
  • Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)

Exclusion

    Key Trial Info

    Start Date :

    February 23 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 25 2022

    Estimated Enrollment :

    238 Patients enrolled

    Trial Details

    Trial ID

    NCT03338218

    Start Date

    February 23 2019

    End Date

    June 25 2022

    Last Update

    August 5 2022

    Active Locations (22)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 6 (22 locations)

    1

    Ziekenhuis Oost-Limburg-ZOL

    Genk, Belgium

    2

    Fakultni nemocnice Brno

    Brno, Czechia

    3

    Military University Hospital

    Prague, Czechia

    4

    CHRU Nancy - Hôpital Central

    Nancy, France